BioSolutions – COOPER GENERAL NEWS

After placing the no-bid contract with Emergent, the Trump administration reverted to traditional contract rules and looked for competitive proposals for additional fillings and packaging, known in the industry as fill-finish work, the documents show. Ology Bioservices, based in Alachua, Fla., Agreed to provide essentially the same services as the Camden and Rockville Emergent plants for three quarters to nearly one third the cost, according to a contract-based calculation.

According to an agreement made in August, Ology would collect state fees of $ 6.83 per vial. By comparison, Emergent’s existing lines would cost between $ 9.03 and $ 18.40 per vial.

A health department spokeswoman said Ology is cheaper in part because it can fill more than 100,000 vials in a single batch, which is five times that of Emergent. This “lowers the price per bottle by spreading the fixed costs over more bottles,” she said in an email.

Even after the launch of Ology, the government continued its higher-cost agreement with Emergent to ensure “additional capacity is available when or when it is needed to fill vaccines or therapeutics,” she said. At the time of the deal, former and current federal officials said the government wanted to secure as much manufacturing capacity as possible before commercial companies buy it out.

Over the years, Emergent has grown by funding the expansion of its manufacturing facilities and the accumulation of product reserves.

In November 2019, the company announced that it would double its sales, including by expanding its contract manufacturing business. A senior vice president, Syed Husain, outlined a “game plan” that would “cross-sell additional services” to existing customers, including the federal government. Six months later, Emergent signed the contract that expanded its existing government contract to include work in its Camden and Rockville locations.

Dr. Robert Kadlec, a former Trump administration official who oversaw the agency that awarded Covid-19 contracts, had previously worked as a consultant for Emergent. Dr. Kadlec has said that he did not negotiate the emergent deal but approved it. Emergent said it negotiated the agreement with professional government officials.

Top House Democrats have launched an investigation into whether Emergent Biosolutions, which recently botched 15 million doses of Covid-19 vaccine, won the federal contract for inclusion because of its cozy relationship with a former top Trump government official.

New York Rep. Carolyn B. Maloney, Chair of the House Committee on Oversight and Reform, and James E. Clyburn of South Carolina, Chair of the Select Subcommittee on Coronavirus Crisis, sent a joint letter to Emergent Solutions CEO Robert G. Kramer and board chairman Fuad El-Hibri demand that they testify before the coronavirus subcommittee.

“In particular, we are investigating reports that Emergent has won multi-million dollar contracts to manufacture coronavirus vaccines, despite a long, documented history of inadequately trained personnel and quality control issues,” the legislature wrote.

The committees deal specifically with the role that Dr. Robert Kadlec, former Emergent Advisor and Trump’s Assistant Secretary for Preparedness and Response, has played in helping the company get the job done. They asked the company to hand over a number of documents, including all federal contracts since 2015, all communications with Kadlec, as well as information on audits and inspections of its facilities, drug pricing and executive compensation.

“Emergent received $ 628 million in June 2020 to set up the primary US vaccine manufacturing facility developed by Johnson & Johnson and AstraZeneca,” lawmakers wrote in a letter sent to Kramer and El-Hibri on Monday . Kadlec “appears to have pushed for this award, although there are indications that Emergent was unable to reliably perform the contract.”

According to the letter, an FDA inspection of the Baltimore plant in April 2020 revealed that Emergent did not have the personnel to manufacture a coronavirus vaccine. Another inspection in June revealed that Emergent’s plan to manufacture much-needed coronavirus vaccines was inadequate due to poorly trained staff and quality control issues.

Despite falling short on federal inspections, the Trump administration paid the company $ 628 million in June to manufacture coronavirus vaccines.

Reports later surfaced indicating quality control issues at Emergent’s Baltimore facility.

“During the manufacturing process, your company contaminated millions of doses of Johnson & Johnson’s one-shot coronavirus vaccine with ingredients from the AstraZeneca vaccine,” the legislature wrote.

Emergent was forced to destroy up to 15 million tainted doses of the Johnson & Johnson vaccine, and an additional 62 million doses remained pending until it was found not to have been mistaken by the York Times.

Emergent’s Baltimore facility has not been approved by the Food and Drug Administration, so none of the cans produced at the site were ever distributed or made it into the arms of the Americans.

“We are concerned about the cost to taxpayers and the potential impact on our country’s vaccination efforts from failed attempts by Emergent to manufacture these vaccines,” the legislature wrote.

Lawmakers also said they are considering Emergent’s role as the sole anthrax vaccine supplier on the Strategic National Stockpile.

“Emergent has increased the government purchase price for the anthrax vaccine by 800% since the drug was purchased in 1998. As a result, nearly half of the SNS budget has been spent on purchasing Emergent’s anthrax vaccine over the past decade,” so the representative wrote.

According to the letter, after Kadlec was confirmed in the Trump administration, Emergent received millions of dollars in federal contracts from his agency, including inventory contracts, “which were put out to tender”.

Emergent encouraged oversight of the inventory to be transferred from the Centers for Disease
Control and Prevention to the Deputy Secretary’s Office for Preparedness and Response under Kadlec’s control according to the letter.

Until 2015, Kadlec Emergent advised through his company RPK Consulting. Kadlec was confirmed as the head of the Office of the Ministry of Health and Human Services in 2017.

Kramer and El-Hibri were asked to testify before the subcommittee on May 19 at 10:30 am ET.